GNH USA

Europe — EMA

Meronem Iv (Meropenem Anhydrous)

GNH USA supplies Meronem Iv (Meropenem), a carbapenem antibiotic for severe intra‑abdominal, urinary, pulmonary and central nervous system infections.

Meropenem Anhydrous

Request sourcing

1
Pack/s

What is Meropenem Anhydrous?

Meropenem, the active ingredient in Meronem Iv, is a carbapenem antibiotic presented as an intravenous solution for intravenous use. It treats severe bacterial infections such as intra‑abdominal sepsis, urinary tract infections, pneumonia, meningitis and septicemia in hospitalized patients.

GNH USA supplies Meronem Iv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Meropenem Anhydrous used for?

Meronem Iv is a broad‑spectrum carbapenem used to treat serious bacterial infections in the hospital setting.

Complicated intra‑abdominal infection: provides rapid bacterial eradication in patients with intra‑abdominal sepsis. Complicated urinary tract infection: clears resistant uropathogens causing pyelonephritis. Hospital‑acquired pneumonia: effective against multidrug‑resistant organisms in ventilated patients. Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis. Septicemia: achieves systemic bacterial clearance in bloodstream infections.

What are the side effects of Meropenem Anhydrous?

Adverse reactions may occur with any intravenous antibiotic. Monitoring is recommended during therapy.

Common Side Effects: - Nausea - Diarrhea - Headache - Rash or pruritus at infusion site - Phlebitis or infusion site pain - Elevated liver enzymes

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disease - Clostridioides difficile‑associated colitis - Anaphylactic or severe allergic reactions - Neutropenia or agranulocytosis - Acute renal failure - Severe electrolyte disturbances

What precautions apply to Meropenem Anhydrous?

Meronem Iv requires careful clinical assessment before and during therapy. - Renal impairment: adjust dose based on creatinine clearance. - CNS disorders: monitor for seizures, especially in patients with a history of epilepsy. - Hypersensitivity: avoid in patients with known carbapenem or β‑lactam allergy. - Concomitant antibiotics: assess for additive nephrotoxicity. - C. difficile risk: monitor for signs of colitis during and after treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Meropenem Anhydrous interact with?

Meronem Iv can alter the pharmacokinetics of several drugs.

Major Interactions (Avoid): - Valproic acid: reduced serum levels, risk of seizure breakthrough. - Oral contraceptives: decreased efficacy, consider alternative contraception. - Probenecid: increased meropenem concentrations, heightened toxicity risk. - Aminoglycosides: additive nephrotoxicity. - Loop diuretics: enhanced renal adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible INR elevation, monitor coagulation. - Phenytoin: altered antiepileptic levels, check serum concentrations. - NSAIDs: increased risk of renal impairment. - Rifampicin: potential reduction in meropenem exposure. - Immunosuppressants: monitor for infection risk.

Frequently asked questions

What is Meronem Iv used for?+
Meronem Iv is indicated for the treatment of serious bacterial infections in hospitalized patients, including complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, bacterial meningitis and septicemia. It is reserved for infections caused by organisms that are susceptible to carbapenem therapy.
How does meropenem work?+
Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to weakened cell walls, osmotic instability and ultimately bacterial cell lysis. Its broad affinity for multiple PBPs gives it activity against many resistant Gram‑negative, Gram‑positive and anaerobic bacteria.
What is the usual dose of Meronem Iv?+
The dose of Meronem Iv is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function and local susceptibility patterns. Typical regimens range from 0.5 g to 2 g administered intravenously every 8 hours, but exact dosing must be determined by the treating physician.
Is Meronem Iv safe in pregnancy or breastfeeding?+
Safety data for meropenem in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as the drug may be excreted in breast milk.
How do I order Meronem Iv from GNH USA?+
To request Meronem Iv, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.
How does Meronem compare with other carbapenems or alternative antibiotics?+
Meropenem offers a broad spectrum of activity, including stability against many extended‑spectrum β‑lactamases, and penetrates the central nervous system better than some carbapenems. Compared with alternatives such as imipenem‑cilastatin, meropenem has a lower risk of seizures and does not require co‑administration of cilastatin, making it a preferred option for many severe infections.
What are the storage and handling requirements for Meronem Iv?+
Meronem Iv must be stored refrigerated at 2 °C to 8 °C, protected from light, and should never be frozen. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept at controlled room temperature if not administered immediately.
How is Meronem Iv administered?+
Meronem Iv is given by intravenous infusion. The powder is reconstituted with the appropriate diluent, then further diluted in compatible IV fluids. Administration is typically over 30 minutes, but infusion time may be adjusted based on patient tolerance and clinical judgment. Infusion sets should be changed after each use.
What are the most serious risks to watch for while receiving Meronem Iv?+
Serious adverse events include seizures, especially in patients with renal dysfunction or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant neutropenia or agranulocytosis. Prompt recognition and medical intervention are essential if any of these occur.
Who should not receive Meronem Iv?+
Meronem Iv is contraindicated in patients with a documented hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of severe seizures, uncontrolled epilepsy, or those receiving concomitant drugs that lower the seizure threshold.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Meropenem Anhydrous
Route
Intravenous Use
Manufacturer
Pfizer S.A.
Origin
EU

Related products

Agenor

Agenor

Meropenem Anhydrous

Medochemie Ltd.
EU
Agenorem

Agenorem

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU